Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy

Abstract

The study was approved by the institutional review board of the University of Pittsburgh Medical Center (IRB#0411029) and registered in clinicaltrials.gov (NCT00177268) as a tissue and blood banking protocol for CTCL patients for current and future CTCL research.

Case Report: Chimeric Antigen Receptor T Cells Induced Late Severe Cytokine Release Syndrome

“…Rubin et al. described four patients with skin lesions attributed to CAR therapy, including two patients with eruptions with unusual mononuclear cell dermal infiltrates and two patients with transient eruptions ( 25 ). Moreover, et al.…”

Rapidly progressing vulvar soft tissue infection as a result of severe hypogammaglobulinemia following CAR T-cell therapy

“…Two patients receiving CAR T-cell therapy developed maculopapular rashes within two weeks of treatment with biopsies showing predominantly lymphocyte infiltration suggestive of an “eruption of lymphocyte recovery.” Another patient presented with skin necrosis due to a staphylococcus infection one day after therapy due to the immunocompromised state. Two other patients presented 5–7 months following therapy with cutaneous papules and pseudovesicles with lymphocytic features ( Rubin et al, 2016 ). Hu et al describes a patient with refractory B-cell lymphoma who received CAR T-cell therapy and developed an acute dermatologic reaction following therapy.…”

A case of B-cell lymphoblastic leukemia cutis flaring following CAR T-cell therapy in a patient with refractory acute lymphoblastic leukemia

“…Dermatologic complications in this series included 1 patient with Merkel cell carcinoma, 2 patients with unusual mononuclear cell dermal infiltrates, and 2 patients with transient eruptions consistent with ''eruption of lymphocyte recovery.'' 4 CAR T-cell therapy has revolutionized the treatment landscape for relapsed refractory hematologic malignancies including ALL, though little is known about its effect on leukemia cutis. Our report documents a clear case of flaring disease in the skin, which resolved spontaneously without further intervention after CAR T-cell therapy.…”